Requests that the FDA confirm that Lisinopril and Hydrochlorothiazide Powder for Oral Suspension is suitable for submission in an Abbreviated New Drug Application.
🏛 Food and Drug Administration (FDA)FDA-2025-P-7282
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.